

Compound 1 monotherapy significantly inhibits vascular pathology
(chronic rejection atherosclerosis)
in murine MHC II mismatched cardiac transplant model




Figure 1

**Compound 1 significantly inhibits chronic rejection vasculopathy in
fully mismatched (MHC I and MHC II disparate)
mouse cardiac allografts***




Figure 2